Literature DB >> 19057990

Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey.

Sevki Cetinkalp1, Muammer Karadeniz, Mehmet Erdogan, Ayhan Zengi, Vildan Cetintas, Asli Tetik, Zuhal Eroglu, Buket Kosova, A Gokhan Ozgen, Fusun Saygili, Candeger Yilmaz.   

Abstract

PURPOSE: Dyslipidemia, cardiovascular disease and hypertension are more frequently seen in patients with PCOS than in normal patients. We aimed at evaluating the distribution of Apo E alleles that can influence cardiovascular risk of the PCOS patients and control subjects.
METHODS: In this study, 129 young women with PCOS and 91 healthy women were included. In all subjects we performed hormonal, biochemical and Apo E genetic analysis.
RESULTS: The Apo E3 allele was found at a significantly higher frequency in the PCOS patient group compared with the control group. The Apo E2 allele was found at a significantly higher frequency in the control group compared with the patient group with PCOS.
CONCLUSIONS: Although there were genotype and allele differences between control and patient groups in this study, no statistically significant change was determined in lipid and other cardiovascular risk factors in connection with allele and genotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19057990      PMCID: PMC2649336          DOI: 10.1007/s10815-008-9280-8

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  35 in total

1.  Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

Authors:  D A Ehrmann; D J Schneider; B E Sobel; M K Cavaghan; J Imperial; R L Rosenfield; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

2.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

3.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  R A Wild; P C Painter; P B Coulson; K B Carruth; G B Ranney
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

4.  Apolipoprotein E alleles and risk of coronary disease. A meta-analysis.

Authors:  P W Wilson; E J Schaefer; M G Larson; J M Ordovas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-10       Impact factor: 8.311

5.  Direct phenotyping of human apolipoprotein E in plasma: application to population frequency distribution in Paris (France).

Authors:  S Bailleul; R Couderc; V Landais; G Lefèvre; D Raichvarg; J Etienne
Journal:  Hum Hered       Date:  1993 May-Jun       Impact factor: 0.444

6.  Underexpression of the apolipoprotein E4 isoform in an Italian population.

Authors:  R W James; M Boemi; R Giansanti; P Fumelli; D Pometta
Journal:  Arterioscler Thromb       Date:  1993-10

7.  The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances.

Authors:  S L Reilly; R E Ferrell; C F Sing
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

Review 8.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

Review 9.  Apolipoprotein E polymorphism and atherosclerosis.

Authors:  J Davignon; R E Gregg; C F Sing
Journal:  Arteriosclerosis       Date:  1988 Jan-Feb

Review 10.  Obesity, lipids, cardiovascular risk, and androgen excess.

Authors:  R A Wild
Journal:  Am J Med       Date:  1995-01-16       Impact factor: 4.965

View more
  4 in total

1.  Effect Of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystıc ovary syndrome.

Authors:  Muammer Karadeniz; Mehmet Erdoğan; Zengi Ayhan; Murat Yalcin; Murat Olukman; Sevki Cetinkalp; Gulinnaz E Alper; Zuhal Eroglu; Asli Tetik; Vildan Cetintas; Ahmet G Ozgen; Fusun Saygili; Candeger Yilmaz
Journal:  Lipids Health Dis       Date:  2011-10-28       Impact factor: 3.876

Review 2.  Cardiometabolic risk in polycystic ovary syndrome.

Authors:  Katica Bajuk Studen; Marija Pfeifer
Journal:  Endocr Connect       Date:  2018-05-29       Impact factor: 3.335

3.  Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Chenchen Zhuang; Xufei Luo; Wenjuan Wang; Runmin Sun; Miaomiao Qi; Jing Yu
Journal:  Front Cardiovasc Med       Date:  2022-02-16

Review 4.  Association between High Serum Homocysteine Levels and Biochemical Characteristics in Women with Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Yuming Meng; Xiang Chen; Zheng Peng; Xuexiang Liu; Yifan Sun; Shengming Dai
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.